Prognostication for early breast cancer (BC) has traditionally relied on clinic-pathologic factors, such as age [1], tumour size [2], hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression [3, 4], as well as nodal status [2, 5]. Here, ERBB2 is linked to breast carcinoma.